Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing’s Disease Published in Lancet Diabetes & Endocrinology
Recordati Rare Diseases announces today that Lancet Diabetes & Endocrinology has published positive results from the Phase III LINC-3 pivotal study of Isturisa®, recently approved for the treatment of endogenous Cushing’s syndrome in adults. Patients with Cushing’s disease, the most common form of endogenous Cushing’s syndrome, have an increased risk of significant comorbidities, including cardiovascular and cerebrovascular diseases as a result of excessive cortisol levels.1 Data from the large LINC-3 study, which enrolled 137 patients with Cushing’s disease, demonstrate that Isturisa® rapidly reduces mUFC and sustains this reduction alongside improvements in comorbidities, clinical signs and patients’ quality of life over 48 weeks.
“The exciting data, published today, underscore the efficacy and safety of Isturisa® in a prospective setting, and represent a significant advance for the management of patients with Cushing’s disease, a serious and potentially life-threatening rare condition,” said Rosario Pivonello, MD, Professor of Endocrinology at the Federico II University of Naples, Italy. “I would like to thank all the patients who participated in the LINC-3 study, and their families, who have helped to bring this new and welcome treatment option to this underserved patient population.”
The LINC-3 study met its primary endpoint, with significantly more patients maintaining normal mUFC with Isturisa® without a dose increase than placebo (86% vs 29%; P <0.0001) 8 following weeks of randomized withdrawal (week 34). further analysis patients’ mufc response found: p>
- Over half (53%) of patients achieved the key secondary endpoint of a normal mUFC after an initial 24 weeks of open-label treatment with Isturisa®, without any dose increase after week 12
- Majority (72%) of patients had normal mUFC at week 12, and two-thirds (66%) of patients had normal mUFC at the end of the 48-week study
- Almost all (96%) patients achieved normal mUFC at some point during the study, with a median time to first complete response of 41 days
Decreases in mUFC levels during treatment with Isturisa® were accompanied by improvements in clinical signs and cardiovascular-related risk factors (weight, BMI, blood glucose, blood pressure, and total cholesterol). Isturisa® is well tolerated, with the most common adverse effects in LINC-3 being nausea (42%), headache (34%), fatigue (28%) and adrenal insufficiency (28%).
“The publication of these data in Lancet Diabetes & Endocrinology confirms Isturisa® as an effective new treatment option for patients with Cushing’s syndrome,” said Andrea Recordati, CEO. “Following the recent approval of Isturisa® in the US and EU, we are excited to bring Isturisa® to all of those patients who need it.”
The full manuscript can be accessed online at:
About Cushing’s syndrome
Cushing’s syndrome is caused by an inappropriate and chronic exposure to excessive levels of cortisol. The source of this excess of cortisol can be endogenous or exogenous (ie medication).2 When the excess cortisol production is triggered by a pituitary adenoma (ie. a tumor of the pituitary gland located in the brain) secreting excess adrenocorticotropic hormone (ACTH), the condition of the patient is defined as Cushing’s disease and comprises about 70% of Cushing’s syndrome cases.2,3 It is a rare, serious and difficult-to-treat disease that affects approximately one to two patients per million per year. Prolonged exposure to elevated cortisol levels is associated with considerable morbidity, mortality and impaired quality of life as a result of complications and comorbidities.4 Normalization of cortisol levels is therefore a primary objective in the treatment of Cushing’s syndrome.5
LINC-3 is a prospective, multicentre, 48-week trial with an 8-week, double-blind, randomized withdrawal phase to evaluate the safety and efficacy of Isturisa® in patients with Cushing’s disease. The primary endpoint in the LINC-3 trial is the proportion of patients randomized to Isturisa® and placebo, separately, at Week 26 with a mUFC ≤ULN at the end of the 8-week randomized withdrawal period (Week 34), without a dose increase during this period. The key secondary endpoint is the proportion of enrolled patients with a mUFC ≤ULN after an initial 24 weeks of open-label treatment with Isturisa® without any dose increase after Week 12. LINC-3 involved 137 patients with persistent or recurrent Cushing’s disease or those with de novo disease who were not candidates for surgery.1
Isturisa® is a potent oral inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyses the final step of cortisol biosynthesis in the adrenal gland. Isturisa® is available as 1 mg, 5 mg and 10 mg film-coated tablets. Isturisa®, indicated for the treatment of adult patients with endogenous Cushing’s syndrome, is now available in France as the first EU country to launch. Isturisa® was granted marketing authorization by the European Commission on 9 January 2020. Please see prescribing information for detailed recommendations for the use of this product.6
- Pivonello R et al. Lancet Diabetes Endocrinol 2020; doi: 10.1016/S2213-8587(20)30240-0 [Epub ahead of print]
- Lacroix A et al. Lancet 2015;386:913–27
- Nieman LK et al. Am J Med 2005;118:1340–6
- Pivonello R et al. Lancet Diabetes Endocrinol 2016;4:611–29
- Nieman LK et al. J Clin Endocrinol Metab 2015;100:2807–31
Isturisa® Summary of Product Characteristics, May 2020
About Recordati Rare Diseases
The company’s EMEA headquarters is located in Puteaux, France, with global headquarter offices located in Milan, Italy.
For a full list of products, please click here: www.recordatirarediseases.com/products .
About the Recordati group
Recordati , established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TENCENT-MARKETING25.9.2020 12:23:16 CEST | Press release
BCG Collaborates with Tencent Marketing Insight to Release 2020 BCG x Tencent Digital Luxury Report
NY-PHILIP-MORRIS-INTL25.9.2020 12:17:14 CEST | Press release
U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update
PA-PALLADIO-BIOSCIENCES25.9.2020 12:11:11 CEST | Press release
Palladio Completes $20 Million Series B Financing
ANT-GROUP25.9.2020 09:56:12 CEST | Press release
Ant Group Launches “Trusple,” an AntChain-Powered Global Trade and Financial Services Platform for SMEs and Financial Institutions
MA-IPSEN25.9.2020 07:02:05 CEST | Press release
Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer
ANT-GROUP25.9.2020 05:47:07 CEST | Press release
Deloitte Launches < "The Next Wave" Emerging Digital Life in South and Southeast Asia > Report At Ant Group’s INCLUSION Fintech Conference
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom